Evidence map›Paper›PMID 40320483›Full record

ReviewClinical reviews in allergy & immunology2025

Mechanisms and Therapeutic Implications of EZH2 in Nasal Diseases.

Jiani Li, Meng Wang, Jing Yang, Zhiwei Cao, Zhaowei Gu, Yunxiu Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiani Li *Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Meng Wang *Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Jing Yang *Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Zhiwei CaoDepartment of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Zhaowei GuDepartment of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. zwgu@cmu.edu.cn.
Yunxiu WangDepartment of Clinical Trial Ward, Clinical Trial and Conversion Center, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. wangyx@cmu.edu.cn.

Funding

345 Talent Project of Shengjing Hospital of China Medical University M0729 and M1391Natural Science Foundation of Liaoning Province 2024-MS-061Science and technology plan projects of Liaoning Province 2023JH2/20200079
6 · The paper itself

Abstract

Enhancer of zeste homolog 2 (EZH2), a protein encoded by the EZH2 gene, is a crucial subunit in polycomb repressive complex 2. EZH2 controls the transcription of genes critical for cell proliferation, differentiation, amplification, and function through both methylated and unmethylated functions. EZH2 is considered to be a transcriptional suppressor protein when it controls histone methylation. Its dysregulation is related to a variety of cancers, with significant evidence showing its role in prostate cancer and breast cancer. EZH2 is also thought to be involved in the differentiation and function of immune cells. Ongoing research on EZH2 has revealed the correlation between inflammatory nasal diseases, the occurrence and development of nasal sinus tumors, and EZH2. This article aimed to review the research progress on the role of EZH2 in nasal diseases and explore the possibility of future EZH2-targeted therapies for nasal diseases.

Indexed as

Enhancer of Zeste Homolog 2 ProteinNose DiseasesAnimalsDisease SusceptibilityGene Expression RegulationHumansMolecular Targeted TherapyEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanAllergic rhinitisAsthma; DZNepEZH2; H3 K27Me3Nose neoplasmsTazemetostat

Identifiers

PMID40320483

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.